Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension
Enrolling by invitation · Phase 4 · NCT07212686
Conditions: Vasodilatory Shock
At a glance
- Research payments reported, 2025
- $39,370
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- Northwell Health (with Innoviva Specialty Therapeutics)
- Tested
- Angiotensin-II (drug)
- Dates
- Started 2025-10-28; completion 2030-06
- Results posted
- Not yet
The goal of this clinical trial is to determine the safety and efficacy of Angiotensin-II in the treatment of pediatric patients in fluid refractory vasodilatory shock. The main questions it aims to answer are: * To evaluate the change in blood pressure or reduction of vasoactive requirements (norepinephrine equivalent dosing) after initiating Angiotensin II * To establish the safety and tolerability of Angiotensin-II in pediatric patients Participants will receive Angiotensin-II in addition to standard of care therapy for vasodilatory shock. * The study team will then monitor the patient's vital signs, blood work, and for any potential side effects from the drug. * An ultrasound will…
From ClinicalTrials.gov, last updated 2026-10-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
La Jolla Pharmaceutical Company reported $39,370 in research payments for this study in 2025 (3 payments).
Products named: Giapreza
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Thefeins the Feinstein Institutes for Medical Research $34,370
- The Feinstein Institutes for Medical Research $5,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.